Abstract: Defibrotide, a polydeoxyribonucleotide, obtained by extraction from animal organs, is the active ingredient of compositions for the treatment of acute states of myocardial ischemia and infarction.
Type:
Grant
Filed:
February 14, 1985
Date of Patent:
September 15, 1987
Assignee:
Crinos Industria Farmacobiologica S.p.A.
Inventors:
Giuseppe Prino, Marisa Mantovani, Riccardo Niada
Abstract: A novel complex of carrageenan and a member of the group consisting of emepronium, doxycycline, and propranolol, pharmaceutical preparations containing such a complex, and its use in medicine.
Type:
Grant
Filed:
June 7, 1985
Date of Patent:
September 15, 1987
Assignee:
KabiVitrum AB
Inventors:
Carl-Aage Bergwitz-Larsen, Rolf G. L. sterlund
Abstract: A novel N-acetylneuraminic acid derivative, represented by the general formula: ##STR1## wherein the R.sup.1 groups are, independently, hydrogen or acetyl; R.sup.2 is a nucleoside residue; and R.sup.3 is carboxyl or methoxycarbonyl.The N-acetylneuraminic acid derivative is useful in inhibiting metastasis of cancer cells. Also provided is a process for the preparation of the derivatives.
Abstract: A high caloric, high fat dietary composition having greater than 2.5 Kcals/ml. is utilizable for enteral hyperalimentation in severe malnutrition. The composition has an increased proportion of fat which gives it a higher caloric density and enables a patient to be fed up to 6000 Kcals/24 hour period.
Abstract: Plant extracts are employed to provide a menses inducing composition for topical application. Common commercially available fenugreek seeds and commercially available ginger are mixed in a preferred range of ratios and combined in a dry powder form for topical application to the outside of the abdomen of the female to induce menses.
Abstract: There is disclosed a process for producing a convalently bound heparin--antithrombin-III complex useful for anticoagulant therapy, a covalently bound heparin--antithrombin-III complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for preventing and treating thromboembolisms by administering to a human patient a therapeutically effective amount of the complex or preparation.
Abstract: Certain 3-oxo-prop-1-enyl purine and pyrimidine derivatives and the corresponding nucleosides have been prepared. These compounds exhibit interesting and valuable cytotoxic activity. This cytotoxicity is of special interest in that it appears to inhibit DNA reproduction without affecting RNA or protein synthesis.
Type:
Grant
Filed:
July 20, 1984
Date of Patent:
August 25, 1987
Assignee:
The Research Foundation of State University of New York
Abstract: A cytosine nucleoside is produced by reacting a peracylcytosine with a hydroxy-protected monosaccharide or a hydroxy-protected nucleoside whose base moiety is other than cytosine and, if necessary, removing the hydroxy-protecting group.
Abstract: A method for regulating the growth processes in a myriad of cells, tissues, organ systems and unicellular and multicellular organisms including plants, animals and man by the administration of effective amounts of the opioid antagonists naloxone, naltrexone, their analogs metabolites derivatives, and/or mixtures thereof. At the cellular level, the growth processes entail all mitotic events and related processes including cell proliferation, as well as cell migration and cell differentiation, and at the somatic or organismal level, anatomical, behavioral and neurological development, metamorphisis and maturation. Growth regulation can be effected in vivo and/or in vitro.
Abstract: Pharmaceutical formulations for the treatment of gastrointestinal disorders, which contain as the active component an effective gastrointestinal disorder alleviating amount of a 1,2-diacylglycero-3-phosphocholine in which 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals having a chain length of 16, 18 or 20 carbon atoms. The mixtures of fatty acid radicals in the acyl groups in the 1- and 2-positions preferably have different compositions. The formulations can also contain other active compounds, in particular those which display injurious gastrointestinal side effects.
Abstract: An analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs is disclosed. This combination has been found to exhibit unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.
Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.
Abstract: Disclosed herein is a novel porous and spherical carbonaceous product having acidic groups, basic groups, phenolic hydroxyl groups and carboxyl groups as functional groups at the following relationships:(1) the equivalent ratio of the acidic groups to the basic groups is in the range of 0.40 to 2.5 and(2) the value obtained by subtracting the amount of the carboxyl groups from the sum of the amounts of the basic groups and the phenolic hydroxylic groups is larger than 0.60, wherein the amount of the above-mentioned functional groups is expressed by milliequivalent/g of the product.The novel porous and spherical carbonaceous product having its groups in the above-mentioned relationships exhibits a specific adsorptive capability in living bodies and particularly useful as a pharmaceutical for treating diseases of the liver and kidney after administered orally.
Abstract: A process is described for the formation of a naturally derived composition comprising carotenes, particularly beta-carotene, in oil. The process involves the direct oil extraction of the carotene from algae. The algae are initially harvested as a water slurry and concentrated, as by flocculation, in the slurry. The concentrated portion of the slurry is then mixed with oil and homogenized to form an oil emulsion. Direct contact of the oil and algae results in a high degree of extraction of the carotene from the algae by the oil. The water/oil emulsion is broken and the oil phase containing the carotene separated as by centrifugation and recovered. The resulting carotene/oil composition is useful as a precursor in formation of Vitamin A in human nutrition. The carotene itself may also have some use as a preventative material for certain types of cancers or in supplementation of poultry and livestock feed.
Abstract: The disclosure is of the use of an injectable formulation of disulfiram for the treatment of alcoholism. One formulation comprises disulfiram and a biodegradable polymer. Another formulation comprises a slurry of disulfiram in normal saline. After injection, disulfiram is released from the injection site in a sustained-release manner.
Abstract: Muscle protein breakdown or degradation may be reduced or inhibited in mammals, particularly humans recovering from surgery or suffering from a muscle wasting disorder, by administering daily doses of alpha-ketoisocaproic acid (ketoleucine) or an appropriate salt of the acid. Seventy millimoles per day of sodium alpha-ketoisocaproate administered for five days after major abdominal surgery was found to significantly reduce urinary 3-methylhistidine/creatinine, which is a measure of muscle protein breakdown, and thereby to improve nitrogen balance.
Type:
Grant
Filed:
October 31, 1985
Date of Patent:
June 30, 1987
Assignee:
The Johns Hopkins University
Inventors:
Mackenzie Walser, Daniel G. Sapir, Peter M. Stewart
Abstract: A new pharmaceutical composition for treating nonlymphatic leukemia, such as granulocytic and monocytic leukemia comprising Harringtonine, Homoharringtonine, Anethole, Oleanolic acid and Ginsenoside and method of making the same.
Abstract: Parasitic and viral diseases are treated with a pyrethroid preferably in the presence of alpha-pinene. Preferred compositions are extracts of pyrethrum with water, aqueous ethyl alcohol, or alpha-pinene.
Abstract: Plasmin inhibitory substances have been found in mammalian omental extracts. The substances all contain lipid components. In addition, related commercially available lipid containing molecules, such as mono-, di-, and trisialogangliosides are found to fossess unexpected plasmin inhibitory properties. This suggests methods of therapy for diseases and conditions where blood clotting and fibrin degradation products, are implicated.
Abstract: A pharmaceutical preparation comprising the methanol extractable components of Phyllanthus niruri L. is administered to patients suffering from hepatitis B virus infection in an amount effective for inhibiting the growth of said virus.
Type:
Grant
Filed:
April 26, 1985
Date of Patent:
June 16, 1987
Assignee:
Fox Chase Cancer Center
Inventors:
Pinayur S. Venkateswaran, Irving Millman, Baruch S. Blumberg